CNS · Cough SuppressantRegulatory Approvalregulatorymid-term

Aurobindo Pharma's Dextromethorphan Polistirex Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:33:18 AM

Assessment confidence: 88% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Aurobindo Pharma's receipt of Abbreviated Approval (AP) for Dextromethorphan Polistirex signifies a notable regulatory milestone that could shift competitive dynamics in the cough suppressant market. Pharma strategy teams should closely monitor this development to assess its implications on market positioning and competitive responses. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for cough suppressants and consider strategic positioning against Aurobindo's offering. The strongest clinical anchor is To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 0 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from This approval may enhance Aurobindo's position in the cough suppressant market, potentially impacting competitors with similar products..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG) (FDA). Sub-indication match (rare disease); Entity match (aurobindo pharma). The AP status indicates a streamlined pathway for Aurobindo's product, which could influence future regulatory strategies for similar products in the CNS therapeutic area.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval may allow Aurobindo to capture market share in the cough suppressant segment, potentially affecting the revenue streams of existing competitors with similar products.
Portfolio teams should assess the competitive landscape for cough suppressants and consider strategic positioning against Aurobindo's offering.

What Would Change This Assessment

This becomes more urgent if Monitor for further developments regarding market entry and any potential competitive responses from other manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (aurobindo pharma)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (aurobindo pharma)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Methamphetamine Isomer Pharmacology in Humans
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Ritu
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Competitors in CNS Therapeutics

Commercial impact

medium

This approval may allow Aurobindo to capture market share in the cough suppressant segment, potentially affecting the revenue streams of existing competitors with similar products.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Aurobindo's product, which could influence future regulatory strategies for similar products in the CNS therapeutic area.

What to watch

Monitor for further developments regarding market entry and any potential competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.